FMR1 and fragile X syndrome: A recent study that examined the impact of selective GSK3- isozyme inhibitors in Fmr1–/– mice, reported that inhibition of GSK-3α by BRD0705, but not GSK-3β, corrected FXS symptoms in the Fmr1–/– mice (McCamphill et al., 2020).